enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Vigabatrin - Wikipedia

    en.wikipedia.org/wiki/Vigabatrin

    Vigabatrin reduced cholecystokinin tetrapeptide-induced symptoms of panic disorder, in addition to elevated cortisol and ACTH levels, in healthy volunteers. [12]Vigabatrin is also used to treat seizures in succinic semialdehyde dehydrogenase deficiency (SSADHD), which is an inborn GABA metabolism defect that causes intellectual disability, hypotonia, seizures, speech disturbance, and ataxia ...

  3. Japanese encephalitis vaccine - Wikipedia

    en.wikipedia.org/wiki/Japanese_encephalitis_vaccine

    Japanese encephalitis vaccines first became available in the 1930s. [3] One of them was an inactivated mouse brain-derived vaccine (the Nakayama and/or Beijing-1 strain), made by BIKEN and marketed by Sanofi Pasteur as JE-VAX, until production ceased in 2005.

  4. Sanofi - Wikipedia

    en.wikipedia.org/wiki/Sanofi

    Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers ...

  5. Clobazam - Wikipedia

    en.wikipedia.org/wiki/Clobazam

    The higher the dosage and the longer the drug is taken, the greater the risk of experiencing unpleasant withdrawal symptoms. Benzodiazepine treatment should only be discontinued via a slow and gradual dose reduction regimen.

  6. Chlorpromazine - Wikipedia

    en.wikipedia.org/wiki/Chlorpromazine

    Chlorpromazine (CPZ), marketed under the brand names Thorazine and Largactil among others, is an antipsychotic medication. [6] It is primarily used to treat psychotic disorders such as schizophrenia. [6]

  7. Why Sanofi Stock Was Robustly Healthy Today - AOL

    www.aol.com/why-sanofi-stock-robustly-healthy...

    Sanofi quoted Houman Ashrafian, its head of research and development, as saying that it "represents an unprecedented breakthrough as a potential first-in-disease treatment option with clinically ...

  8. Sanofi wins US approval for multiple myeloma drug in newly ...

    www.aol.com/news/sanofi-wins-us-approval-drug...

    -The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's Sarclisa infusion as a treatment for certain types of newly diagnosed ...

  9. ACAM2000 - Wikipedia

    en.wikipedia.org/wiki/ACAM2000

    ACAM2000 is a vaccine developed by Acambis, which was acquired by Sanofi Pasteur in 2008, before selling the smallpox vaccine to Emergent Biosolutions in 2017. Six strains of vaccinia were isolated from 3,000 doses of Dryvax and found to exhibit significant variation in virulence.